NVO — Novo Nordisk A/S

Novo Nordisk Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Reported Sales: Increased by 32% to DKK 96.8 billion.
• Adjusted Sales: Decreased by 4% at constant exchange rates (CER), primarily due to lower realized prices, despite GLP-1 volume growth.
• U.S. Operations: Sales decreased by 11%, while International Operations grew by 6%.
• Gross Margin: Adjusted gross margin fell to 80.6% from 83.5% in 2025.
• Adjusted Operating Profit: Decreased by 6% at CER.
• R&D Investment: Approximately DKK 22 billion in Q1.
• Shareholder Returns: Nearly DKK 38 billion returned through dividends and share buybacks.

2. Strategic Updates and Business Highlights

• Obesity Treatment: Over 4 million people are now using Novo Nordisk's obesity treatments, a 50% increase from the previous year.
• Wegovy Pill Launch: The oral Wegovy pill has seen over 1 million users since its launch 16 weeks ago, with 1.3 million total prescriptions in Q1.
• High-Dose Wegovy: The 7.2 mg dose has been launched in multiple markets, showing promising weight loss results.
• Regulatory Approvals: Six regulatory approvals and over ten clinical trial initiations in Q1.
• Market Position: Novo Nordisk remains the volume market leader in GLP-1 treatments, with a 55% market share in international operations.

3. Forward Guidance and Outlook

• Adjusted Sales Growth: Expected to decline between 4% and 12% at CER for 2026, reflecting competitive pressures and pricing dynamics.
• Operating Profit Growth: Also expected to decline by 4% to 12% at CER.
• Pipeline Progress: Continued investment in R&D and commercial initiatives, with multiple trials and product launches planned throughout the year.

4. Challenges and Points of Concern

• Price Erosion: The U.S. market is experiencing significant price erosion, estimated at 10% to 15% for Ozempic.
• Competitive Pressures: Intensifying competition in the GLP-1 market, particularly in the U.S., and the impact of reduced Medicaid coverage for obesity medications.
• Employee Reduction: The workforce has decreased by nearly 10,000 employees year-over-year, raising concerns about operational capacity.
• Market Dynamics: Potential negative impacts from the expiration of semaglutide patents and the introduction of generics in various markets, including Canada.

5. Notable Q&A Insights

• Oral Wegovy Titration: Early data shows titration patterns comparable to injectable Wegovy, with a focus on user experience.
• SG&A Spending: A one-time legal provision adjustment impacted SG&A, which is expected to remain disciplined moving forward.
• Pricing Strategy: Management believes current pricing for the Wegovy pill is optimal, with no immediate plans to lower prices despite competitive pressures.
• Future Growth Areas: Management emphasized the importance of diversifying growth through rare diseases and expanding the product pipeline.

This summary encapsulates the key financial metrics, strategic initiatives, future outlook, and challenges faced by Novo Nordisk as discussed in the Q1 2026 earnings call.